SUNNIFORECAST Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC (Aktiv)
UC02-PSMA-01 Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker (Aktiv)
Erstlinie
BP39365 This is an open-label, multi-center, randomized, Phase 1b, adaptive, clinical study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary therapeutic activity of RO6874281 in combination with atezolizumab with/without bevacizumab in participants with unresectable advanced and/or metastatic RCC. The study will consist of a dose-escalation part and an extension part (Aktiv)
MK-3475-905 Randomisierte Phase-3-Studie zur Bewertung der Zystektomie mit perioperativer Pembrolizumab und Zystektomie mit perioperativem Enfortumab Vedotin und Pembrolizumab versus Zystektomie allein bei Cisplatin-ineligiblen Teilnehmern mit muskelinvasiver Blase Krebs (KEYNOTE-905/EV-303) (Aktiv)
Randomet2017 Randomized multi-centre open-label non-inferiority phase 3 clinical trial for patients with a stage IV childhood renal tumor comparing upfront Vincristine, Actinomycin-D and Doxorubicin (VAD, standard arm) with upfront Vincristine, Carboplatin and Etoposide (VCE, experimental arm) (Aktiv)
Zweitlinie oder später
CNIR178X2201 Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)
CVPM087A2101 Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (Aktiv)
CaboPoint (Ipsen) Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors (Aktiv)
IO-PAZ Study of efficacy and safety of pazopanib in patients with advanced and/or metastatic renal cell carcinoma after prior checkpoint inhibitor treatment (Aktiv)
MK-7684A-005 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (Aktiv)